{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:37:55Z","timestamp":1782981475595,"version":"3.54.5"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1194358"],"award-info":[{"award-number":["GNT1194358"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcf.2026.03.018","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:47:19Z","timestamp":1774442839000},"page":"437-442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Updates on pancreas exocrine function in cystic fibrosis for the era of highly effective modulator therapy"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6430-1924","authenticated-orcid":false,"given":"Mitchell L","family":"Ramsey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Y","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jcf.2026.03.018_bib0001","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcf.2026.03.018_bib0002","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.gastro.2010.09.046","article-title":"Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis","volume":"140","author":"Ooi","year":"2011","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jcf.2026.03.018_bib0003","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","article-title":"A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto","volume":"41","author":"Corey","year":"1988","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.jcf.2026.03.018_bib0004","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","article-title":"Cystic Fibrosis of the Pancreas and its relation to Celiac disease: a clinical and pathologic study","volume":"56","author":"Andersen","year":"1938","journal-title":"Am J Dis Child"},{"issue":"3","key":"10.1016\/j.jcf.2026.03.018_bib0005","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jpeds.2004.04.049","article-title":"Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis","volume":"145","author":"Borowitz","year":"2004","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.jcf.2026.03.018_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71168","article-title":"Prenatal Elexacaftor\/Tezacaftor\/Ivacaftor treatment prevents meconium ileus, but not exocrine pancreatic insufficiency and lung disease in infants with cystic fibrosis","volume":"60","author":"Aleksander","year":"2025","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.jcf.2026.03.018_bib0007","first-page":"1023","article-title":"Cystic fibrosis transmembrane conductance regulator modulators reduce the risk of recurrent acute pancreatitis among adult patients with pancreas sufficient cystic fibrosis","volume":"19","author":"Akshintala","year":"2019","journal-title":"Off J Int Assoc Pancreatol (IAP) [et al]"},{"issue":"2","key":"10.1016\/j.jcf.2026.03.018_bib0008","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jcf.2022.08.008","article-title":"Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: a scoping review","volume":"22","author":"Ramsey","year":"2023","journal-title":"Off J Eur Cyst Fibros Soc"},{"issue":"1","key":"10.1016\/j.jcf.2026.03.018_bib0009","first-page":"168","article-title":"Staging exocrine pancreatic dysfunction","volume":"22","author":"Khan","year":"2022","journal-title":"Off J Int Assoc Pancreatol (IAP) [et al]"},{"issue":"5","key":"10.1016\/j.jcf.2026.03.018_bib0010","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1053\/j.gastro.2023.07.007","article-title":"AGA Clinical Practice update on the Epidemiology, evaluation, and management of exocrine pancreatic insufficiency: expert review","volume":"165","author":"Whitcomb","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcf.2026.03.018_bib0011","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000003792","article-title":"Validation of dried blood spot immunoreactive trypsinogen as a biomarker of exocrine pancreas function in children with Pancreas disease","author":"Gummadi","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jcf.2026.03.018_bib0012","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/(SICI)1099-0496(200003)29:3<172::AID-PPUL3>3.0.CO;2-1","article-title":"Evaluation of fecal pancreatic elastase-1 as a measure of pancreatic exocrine function in children with cystic fibrosis","volume":"29","author":"Cade","year":"2000","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.jcf.2026.03.018_bib0013","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-1784","article-title":"Clinical practice guidelines from the Cystic Fibrosis Foundation for preschoolers with Cystic Fibrosis","volume":"137","author":"Lahiri","year":"2016","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.jcf.2026.03.018_bib0014","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.clnu.2016.03.004","article-title":"ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis","volume":"35","author":"Turck","year":"2016","journal-title":"Clin Nutr"},{"issue":"8","key":"10.1016\/j.jcf.2026.03.018_bib0015","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1651-2227.2004.tb02715.x","article-title":"Faecal elastase-1 test is superior to faecal lipase test in the assessment of exocrine pancreatic function in cystic fibrosis","volume":"93","author":"Walkowiak","year":"2004","journal-title":"Acta Paediatr (Oslo Nor: 1992)"},{"issue":"5","key":"10.1016\/j.jcf.2026.03.018_bib0016","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MOG.0000000000000951","article-title":"Evaluation and management of exocrine pancreatic insufficiency: pearls and pitfalls","volume":"39","author":"Ramsey","year":"2023","journal-title":"Curr Opin Gastroenterol"},{"issue":"4","key":"10.1016\/j.jcf.2026.03.018_bib0017","article-title":"Gastrointestinal pathologies in pediatric patients with cystic fibrosis undergoing endoscopy: a single-center retrospective review over 15 years","volume":"16","author":"Blaseg","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jcf.2026.03.018_bib0018","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S1569-1993(15)30165-X","article-title":"Cessation of pancreatic enzyme replacement therapy (PERT) after initiation of therapy with ivacaftor-a case series","volume":"14","author":"Cheah","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.018_bib0019","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/S1569-1993(15)30503-8","article-title":"Partial recovery of exocrine pancreatic function and intestinal fat absorption after ivacaftor treatment","volume":"14","author":"Zwolsman","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.018_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.914790","article-title":"The exocrine pancreas in cystic fibrosis in the era of CFTR modulation: a mini review","volume":"10","author":"McKay","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jcf.2026.03.018_bib0021","unstructured":"National Library of Medicine (U.S.). (2024). Oral CDX-7108 in healthy adults and EPI subjects. (Identifier: NCT05082051). Retrieved January 20, 2026, from https:\/\/clinicaltrials.gov\/study\/NCT05082051."},{"key":"10.1016\/j.jcf.2026.03.018_bib0022","unstructured":"National Library of Medicine (U.S.). (2024). Phase 1 study to assess safety and efficacy of ANG-003. (Identifier: NCT06052293). Retrieved January 20, 2026, from https:\/\/clinicaltrials.gov\/study\/NCT06052293."},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2026.03.018_bib0023","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in cystic fibrosis","volume":"16","author":"Singh","year":"2017","journal-title":"Off J Eur Cyst Fibros Soc"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2026.03.018_bib0024","first-page":"S44","article-title":"Pancreas and pancreatitis: exocrine pancreatic insufficiency","volume":"59","author":"Ramsey","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcf.2026.03.018_bib0025","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jcf.2023.08.013","article-title":"Incidence of fibrosing colonopathy with pancreatic enzyme replacement therapy in patients with cystic fibrosis","volume":"22","author":"Chiuve","year":"2023","journal-title":"Off J Eur Cyst Fibros Soc"},{"issue":"5","key":"10.1016\/j.jcf.2026.03.018_bib0026","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0022-3476(95)70153-2","article-title":"Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee","volume":"127","author":"Borowitz","year":"1995","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jcf.2026.03.018_bib0027","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/MED.0000000000000047","article-title":"Pancreas development in humans","volume":"21","author":"Pan","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.jcf.2026.03.018_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.909648","article-title":"Development of the human pancreas and its exocrine function","volume":"10","author":"Mehta","year":"2022","journal-title":"Front Pediatr"},{"issue":"3\u20134","key":"10.1016\/j.jcf.2026.03.018_bib0029","first-page":"202","article-title":"Changes in pancreatic exocrine secretion with age: pancreatic exocrine secretion does decrease in the elderly","volume":"50","author":"Laugier","year":"1991","journal-title":"Digestion"},{"issue":"5","key":"10.1016\/j.jcf.2026.03.018_bib0030","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/716100784","article-title":"Inspissation of pancreatic zymogen material in cystic fibrosis","volume":"27","author":"Tucker","year":"2003","journal-title":"Ultrastruct Pathol"},{"issue":"3","key":"10.1016\/j.jcf.2026.03.018_bib0031","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1203\/00006450-198603000-00002","article-title":"Age-related alterations of immunoreactive pancreatic cationic trypsinogen in sera from cystic fibrosis patients with and without pancreatic insufficiency","volume":"20","author":"Durie","year":"1986","journal-title":"Pediatr Res"},{"issue":"10","key":"10.1016\/j.jcf.2026.03.018_bib0032","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1203\/00006450-198110000-00010","article-title":"Plasma immunoreactive pancreatic cationic trypsinogen in cystic fibrosis: a sensitive indicator of exocrine pancreatic dysfunction","volume":"15","author":"Durie","year":"1981","journal-title":"Pediatr Res"},{"issue":"3","key":"10.1016\/j.jcf.2026.03.018_bib0033","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-3476(95)70072-2","article-title":"Longitudinal evaluation of serum trypsinogen measurement in pancreatic-insufficient and pancreatic-sufficient patients with cystic fibrosis","volume":"127","author":"Couper","year":"1995","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jcf.2026.03.018_bib0034","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1203\/00006450-199208000-00011","article-title":"Decline of exocrine pancreatic function in cystic fibrosis patients with pancreatic sufficiency","volume":"32","author":"Couper","year":"1992","journal-title":"Pediatr Res"},{"issue":"5","key":"10.1016\/j.jcf.2026.03.018_bib0035","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2026.03.018_bib0036","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1016\/S1569-1993(25)01956-3","article-title":"Understanding the role of CFTR in pancreatic progenitor development to target exocrine pancreatic insufficiency","volume":"24","author":"Ryan","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2026.03.018_bib0037","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"Off J Eur Cyst Fibros Soc"},{"issue":"7","key":"10.1016\/j.jcf.2026.03.018_bib0038","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir med"},{"key":"10.1016\/j.jcf.2026.03.018_bib0039","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1016\/S1569-1993(25)02245-3","article-title":"Quality Improvement project to evaluate pancreatic function through fecal elastase testing in patients that started treatment with elexacaftor\/tezacaftor\/ivacaftor between 2 and 5 years of age","volume":"24","author":"Ward","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.018_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(25)02224-6","article-title":"608 Unlocking pancreatic pathways: investigating the impact of CFTR modulators on pancreatic function in cystic fibrosis","volume":"24","author":"Vallurupalli","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.018_bib0041","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1016\/S1569-1993(25)02187-3","article-title":"571 The prevalence of improved exocrine pancreatic function among cystic fibrosis pediatric patients age 2 years and older on cystic fibrosis transmembrane conductance regulator modulator drug therapies","volume":"24","author":"Tun","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"485","key":"10.1016\/j.jcf.2026.03.018_bib0042","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.jcf.2026.03.018_bib0043","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1038\/ctg.2017.10","article-title":"Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation","volume":"8","author":"Gelfond","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"SUPPL 2","key":"10.1016\/j.jcf.2026.03.018_bib0044","first-page":"132","article-title":"The effect of ivacaftor\/lumacaftor on gastrointestinal function in subjects with CF homozygous for f508del mutation","volume":"55","author":"De Monestrol","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2026.03.018_bib0045","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jcf.2020.12.002","article-title":"Changes in fecal microbiota with CFTR modulator therapy: a pilot study","volume":"20","author":"Pope","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.018_bib0046","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J Pediatr"},{"issue":"9","key":"10.1016\/j.jcf.2026.03.018_bib0047","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for Cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jcf.2026.03.018_bib0048","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/apm.13453","article-title":"Real-world data confirm elexacftor\/tezacaftor\/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis","volume":"132","author":"Bryrup","year":"2024","journal-title":"Acta Pathol Microbiol Immunol Scand"},{"issue":"8","key":"10.1016\/j.jcf.2026.03.018_bib0049","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1002\/ppul.24353","article-title":"Time for a gut check: pancreatic sufficiency resulting from CFTR modulator use","volume":"54","author":"Megalaa","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.03.018_bib0050","article-title":"CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis","author":"Gould","year":"2021","journal-title":"Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2026.03.018_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2026.01.008","article-title":"CFTR modulators reduce acute pancreatitis episodes in individuals with CFTR-related disorders: a case series","author":"Ramsey","year":"2026","journal-title":"J cyst fibros: off j Eur Cyst Fibros Soc"},{"issue":"5","key":"10.1016\/j.jcf.2026.03.018_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0284651","article-title":"Validation of an omega-3 substrate challenge absorption test as an indicator of global fat lipolysis","volume":"18","author":"Freedman","year":"2023","journal-title":"PloS one"},{"issue":"8","key":"10.1016\/j.jcf.2026.03.018_bib0053","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/jcph.484","article-title":"Malabsorption blood test: assessing fat absorption in patients with cystic fibrosis and pancreatic insufficiency","volume":"55","author":"Mascarenhas","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jcf.2026.03.018_bib0054","first-page":"344","article-title":"Preliminary proposals for the follow-up of infants born to mothers with cystic fibrosis treated with CFTR modulators during the first two years of life","volume":"32","author":"Reix","year":"2025","journal-title":"Organe Off Soc Fr Pediatrie"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:44:26Z","timestamp":1781883866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326000858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1569199326000858"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.03.018","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on pancreas exocrine function in cystic fibrosis for the era of highly effective modulator therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}